AbbVie Inc. reported third-quarter 2025 adjusted EPS of $1.86, beating estimates. Revenues of $15.78 billion exceeded expectations, driven by strong sales of key drugs like Rinvoq and Skyrizi. Humira sales declined due to loss of exclusivity in the United States. AbbVie raised its 2025 EPS guidance to $10.61-$10.65.

In immunology, Rinvoq and Skyrizi saw significant sales growth, driven by market share gains. AbbVie’s neuroscience portfolio also performed well, with higher sales of Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta. Sales from the oncology franchise declined slightly, led by lower Imbruvica sales but offset by growth in Venclexta and other newer drugs.

AbbVie’s aesthetics portfolio sales declined, impacting overall revenues. Adjusted SG&A expenses rose 2.6%, while R&D expenses increased by 9.8%. Despite challenges in certain segments, AbbVie remains focused on long-term growth through M&A activity and innovation.

The company’s stock has gained 28% year-to-date, outperforming the industry. AbbVie is actively diversifying its pipeline and portfolio through acquisitions and new drug approvals. Recent submissions to the FDA for new drugs in oncology and neuroscience reflect AbbVie’s commitment to sustainable growth.

AbbVie’s results were a mixed bag, with strong performance in certain segments offset by challenges in others. Shares traded lower pre-market due to softer aesthetics sales. The company’s focus on expanding its oncology and neuroscience footprint through M&A activity and internal innovation is a key driver of future growth.

Read more at Nasdaq: AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised